. 2016 Jun 1;128(3):331–336. doi: 10.1182/blood-2016-02-702761

Table 1.

Monotherapy studies of idelalisib in patients with NHL

First author	Phase	Population	n	ORR (CR)	Median DOR
Flinn²⁸	1	Relapsed/refractory indolent B-cell NHL	64	47 (2)	18.4 mo
Kahl²⁴	1	Relapsed/refractory MCL	39	40 (5)	2.7 mo
Gopal¹⁹	2	Relapsed/refractory indolent B-NHL	125	57 (6)	12.5 mo